Treatment of myeloma bone disease with proteasomal and NF-KappaB activity inhibitors

摘要

The present invention involves the identification and use of compositions for treating myeloma bone disease. The compositions inhibit proteasomal activity and decrease the activity of the transcription factor NF-kappaB. Assessment of a candidate compound for its ability to inhibit production or activity of proteasomal enzymes or NF-kappaB provides a useful means to identify agents to treat myeloma bone disease.